glp-1 bowel obstruction law firm in kentucky Wegovy Lawsuit Alleges Weight-Loss Injections Caused Gastroparesis Targeting Metabolic Dysfunction in Parkinson's
Description
It is worth noting that the weight loss and metabolic improvements achieved with GLP-1 agonists may actually reduce overall thrombotic risk over time by addressing several modifiable risk factors
Apply case-based strategies to improve patient outcomes and support adherence
Cost was noted to be a significant factor for patients in the USA compared to other EU countries, with 48.6% of patients reporting discontinuation due to cost in the USA vs
10.1016/j.pneurobio.2013.06.004
Collectively, these data suggest that GLP-1RA-related hypoglycemia is severe, despite the low risk of death
Estimates suggest that 50% to 96% of patients gain weight during or after treatment, with average increases ranging from 1 to 5 kg within the first year [19]
